Related Experiment Video
Updated: Mar 11, 2026

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones
Published on: July 25, 2019
Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer
Arianna Bellazzo1,2, Giulio Di Minin3, Licio Collavin1,2
1Laboratorio Nazionale CIB, AREA Science Park, Trieste 34149, Italy.
Abstract:
One of the most defining features of cancer is aberrant cell communication; therefore, a molecular understanding of the intricate network established among tumor cells and their microenvironment could significantly improve comprehension and clinical management of cancer. The tumor suppressor DAB2IP (Disabled homolog 2 interacting protein), also known as AIP1 (ASK1 interacting protein), has an important role in this context, as it modulates signal transduction by multiple inflammatory cytokines and growth factors. DAB2IP is a Ras-GAP, and negatively controls Ras-dependent mitogenic signals. In addition, acting as a signaling adaptor, DAB2IP modulates other key oncogenic pathways, including TNFα/NF-κB, WNT/β-catenin, PI3K/AKT, and androgen receptors. Therefore, DAB2IP inactivation can provide a selective advantage to tumors initiated by a variety of driver mutations. In line with this role, DAB2IP expression is frequently impaired by methylation in cancer. Interestingly, recent studies reveal that tumor cells can employ other sophisticated mechanisms to disable DAB2IP at the post-transcriptional level. We review the mechanisms and consequences of DAB2IP inactivation in cancer, with the purpose to support and improve research aimed to counteract such mechanisms. We suggest that DAB2IP reactivation in cancer cells could be a strategy to coordinately dampen multiple oncogenic pathways, potentially limiting progression of a wide spectrum of tumors.
Insights
The tumor suppressor DAB2IP (Disabled homolog 2 interacting protein) is crucial for regulating cancer cell communication. Reactivating DAB2IP may offer a strategy to inhibit multiple cancer-promoting pathways.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Aberrant cell communication is a hallmark of cancer, necessitating a deeper understanding of tumor microenvironment interactions.
- DAB2IP (Disabled homolog 2 interacting protein), also known as AIP1 (ASK1 interacting protein), is a tumor suppressor involved in modulating inflammatory and growth factor signaling pathways.
- DAB2IP functions as a Ras-GAP, negatively regulating Ras-dependent mitogenic signals, and also acts as a signaling adaptor for oncogenic pathways like TNFα/NF-κB, WNT/β-catenin, PI3K/AKT, and androgen receptors.
Purpose of the Study:
- To review the mechanisms and consequences of DAB2IP inactivation in cancer.
- To support and improve research aimed at counteracting DAB2IP inactivation mechanisms.
- To propose DAB2IP reactivation as a potential therapeutic strategy for various cancers.
Main Methods:
- Literature review of DAB2IP's role in cancer signaling.
- Analysis of DAB2IP inactivation mechanisms, including methylation and post-transcriptional regulation.
- Evaluation of DAB2IP's impact on multiple oncogenic pathways.
Main Results:
- DAB2IP inactivation provides a selective advantage to tumors with various driver mutations.
- DAB2IP expression is frequently impaired by methylation in cancer.
- Tumor cells utilize post-transcriptional mechanisms to disable DAB2IP.
Conclusions:
- DAB2IP plays a critical role in controlling key oncogenic signaling pathways.
- Inactivation of DAB2IP contributes to tumor progression.
- Reactivation of DAB2IP could simultaneously inhibit multiple oncogenic pathways, potentially limiting the progression of diverse tumors.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
The JAK-STAT Signaling Pathway
Negative Regulator Molecules

